NASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis $26.30 -1.10 (-4.01%) As of 11:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About IDEAYA Biosciences Stock (NASDAQ:IDYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IDEAYA Biosciences alerts:Sign Up Key Stats Today's Range$26.32▼$27.5350-Day Range$27.40▼$39.7152-Week Range$26.32▼$42.68Volume323,998 shsAverage Volume1.03 million shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$49.55Consensus RatingModerate Buy Company Overview IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations. These candidates remain under clinical investigation; IDEAYA does not sell approved medicines. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and advances clinical development programs, including through collaborations with other biotechnology and pharmaceutical companies. Yujiro S. Hata is the company’s chief executive officer.AI Generated. May Contain Errors. Read More IDEAYA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreIDYA MarketRank™: 3.065182617965 of 5 starsIDEAYA Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 326th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialIDEAYA Biosciences has a consensus price target of $49.55, representing about 80.8% upside from its current price of $27.40.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEAYA Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($4.63) to ($4.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.94% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 8.87.Change versus previous monthShort interest in IDEAYA Biosciences has recently decreased by 9.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentIDEAYA Biosciences has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.MarketBeat FollowsOnly 1 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $985,305.00 in company stock.Percentage Held by Insiders4.70% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEAYA Biosciences' insider trading history. Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDYA Stock News HeadlinesIs IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?November 18 at 1:16 AM | finance.yahoo.comIdeaya Biosciences: Staying Bullish On Darovasertib NDA Submission And MoreNovember 17 at 8:16 PM | seekingalpha.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 18 at 1:00 AM | Profits Run (Ad)IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 17 at 10:02 AM | seekingalpha.comIDEAYA Gains FDA Alignment On Registrational Trial Designs Of IDE849 For Neuroendocrine CarcinomasNovember 17 at 10:02 AM | rttnews.comIDEAYA Biosciences (IDYA) vs. The Competition Financial SurveyNovember 17 at 2:33 AM | americanbankingnews.comTranscript : IDEAYA Biosciences, Inc. - Special CallNovember 16 at 6:37 PM | marketscreener.comMIDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a ...November 16 at 6:37 PM | finance.yahoo.comSee More Headlines IDYA Stock Analysis - Frequently Asked Questions How have IDYA shares performed this year? IDEAYA Biosciences' stock was trading at $34.57 at the beginning of 2026. Since then, IDYA stock has decreased by 20.7% and is now trading at $27.40. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its earnings results on Tuesday, November, 3rd. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.18) by $0.04. The firm's quarterly revenue was up 14.6% on a year-over-year basis. When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' top institutional shareholders include State Street Corp (4.06%), Goldman Sachs Group Inc. (1.50%), Candriam S.C.A. (1.26%) and Fisher Asset Management LLC (0.84%). Insiders that own company stock include Yujiro S Hata, Jeffrey Stein, Briseno Andres Ruiz and Michael Anthony White. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Micron Technology (MU), Iovance Biotherapeutics (IOVA), Advanced Micro Devices (AMD), Tesla (TSLA) and Plug Power (PLUG). Company Calendar Last Earnings11/03/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, IDYA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IDYA CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees145Year Founded2015Price Target and Rating Average Price Target for IDEAYA Biosciences$49.55 High Price Target$66.00 Low Price Target$35.00 Potential Upside/Downside+88.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($4.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$113.70 million Net Margins-1,157.18% Pretax Margin-1,149.62% Return on Equity-39.78% Return on Assets-36.25% Debt Debt-to-Equity RatioN/A Current Ratio9.04 Quick Ratio9.04 Sales & Book Value Annual Sales$218.71 million Price / Sales11.63 Cash FlowN/A Price / Cash FlowN/A Book Value$11.29 per share Price / Book2.33Miscellaneous Outstanding Shares96,690,000Free Float92,150,000Market Cap$2.54 billion OptionableOptionable Beta0.08 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:IDYA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.